Key Drivers
- High profitability
- Solid cash flow
- Elevated leverage
AIAI Summary
WAT's investment case has shifted from pure high‑margin organic growth to a leverage- and integration‑dependent bet—management's BD Biosciences acquisition and $3.5B note financing could materially expand recurring revenue and TAM if cross‑sell synergies and subscription conversions preserve free cash flow, but investors should prioritize monitoring quarterly FCF, interest expense/coverage, and early synergy realization as the decisive catalysts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Solid cash flow
- •Elevated leverage
WAT delivers strong margins, high ROIC/ROE and robust free cash flow but carries material debt, heavy intangible assets and rich valuation with no dividends.
Price Behavior
Key Price Behavior Insights:
- •Strong downtrend
- •Failed reclaim
- •Oversold/volatile
WAT is in a clear short-term downtrend—about a 20% drop from the low–mid $380s to the high $200s in the last month, failing to reclaim $319–333 and sitting below short-term averages, creating oversold but volatile mean-reversion risk.
~20% fall from low–mid $380s to high $200s in the last month signaling sharp selling pressure
Sentiment & News
Key News Insights:
- •$3.5B financing
- •Post‑earnings weakness
- •Product launch
Waters priced a $3.5B multi‑maturity debt deal amid product launches and conference outreach, but faces post‑earnings share weakness and mixed investor positioning.
The large note offering funds growth/opportunistic moves but heightens leverage risk while recent weakness and shifting holders could pressure near‑term stock performance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings